NCT03374228 is a Phase 1 clinical trial of BMS-986205 in Healthy Participants, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT03374228?

NCT03374228 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT03374228?

Interventions in NCT03374228: BMS-986205.

What condition does NCT03374228 study?

NCT03374228 studies Healthy Participants.

Is NCT03374228 still recruiting?

NCT03374228 is currently completed. Last updated 28 June 2018.

Last reviewed 2018-06-28 · How we verify

NCT03374228

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Bioavailability of BMS-986205

Completed Phase 1 Last updated 28 June 2018

What this trial tests

Phase 1 trial testing BMS-986205 in Healthy Participants in 7 participants. Completed in 16 February 2018.

Timeline

4 January 2018

Primary endpoint
16 February 2018

16 February 2018

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	7
Start date	4 January 2018
Primary completion	16 February 2018
Estimated completion	16 February 2018
Sites	1 location across United Kingdom

Drugs / interventions tested

BMS-986205 — full drug profile →

Conditions studied

Healthy Participants — all drugs for Healthy Participants →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

Adults 18 to 50, any sex, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assess the absolute bioavailability of a tablet formulation of BMS-986205 following simultaneous oral administration of BMS-986205 and intravenous infusion of \[13C\]BMS-986205 solution for intravenous administration in healthy participants.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.
Tang K, Wu YH, Song Y, Yu B. · · 2021 · cited 276× · PMID 33883013 · DOI 10.1186/s13045-021-01080-8
The Role of Indoleamine 2, 3-Dioxygenase 1 in Regulating Tumor Microenvironment.
Huang X, Zhang F, Wang X, Liu K. · · 2022 · cited 38× · PMID 35681736 · DOI 10.3390/cancers14112756
The immunomodulatory role of IDO1-Kynurenine-NAD<sup>+</sup> pathway in switching cold tumor microenvironment in PDAC.
Anu RI, Shiu KK, Khan KH. · · 2023 · cited 12× · PMID 37456260 · DOI 10.3389/fonc.2023.1142838

Verify or expand the search:

Other trials of BMS-986205

Trials testing the same drug.

NCT04007588 — A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) a · Phase 2 · withdrawn
NCT03936374 — A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants · Phase 1 · completed
NCT03792750 — A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors · Phase 1, PHASE2 · completed
NCT03519256 — A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG · Phase 2 · terminated
NCT03459222 — An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spre · Phase 1, PHASE2 · completed

Other recruiting trials for Healthy Participants

Currently open trials in the same condition.

NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03374228 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 28 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03374228.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing